AU2006245440B2 - Immunogens for meningitidis-A vaccines - Google Patents

Immunogens for meningitidis-A vaccines Download PDF

Info

Publication number
AU2006245440B2
AU2006245440B2 AU2006245440A AU2006245440A AU2006245440B2 AU 2006245440 B2 AU2006245440 B2 AU 2006245440B2 AU 2006245440 A AU2006245440 A AU 2006245440A AU 2006245440 A AU2006245440 A AU 2006245440A AU 2006245440 B2 AU2006245440 B2 AU 2006245440B2
Authority
AU
Australia
Prior art keywords
oligosaccharide
mannose
protein
linkage
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006245440A
Other languages
English (en)
Other versions
AU2006245440A1 (en
Inventor
Paolo Costantino
Stefan Oscarson
Peter Teodorovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36942242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006245440(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics SRL filed Critical Novartis Vaccines and Diagnostics SRL
Publication of AU2006245440A1 publication Critical patent/AU2006245440A1/en
Application granted granted Critical
Publication of AU2006245440B2 publication Critical patent/AU2006245440B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006245440A 2005-05-06 2006-05-08 Immunogens for meningitidis-A vaccines Ceased AU2006245440B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67828905P 2005-05-06 2005-05-06
US60/678,289 2005-05-06
PCT/IB2006/001703 WO2006120576A2 (en) 2005-05-06 2006-05-08 Immunogens for meningitidis-a vaccines

Publications (2)

Publication Number Publication Date
AU2006245440A1 AU2006245440A1 (en) 2006-11-16
AU2006245440B2 true AU2006245440B2 (en) 2012-04-19

Family

ID=36942242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006245440A Ceased AU2006245440B2 (en) 2005-05-06 2006-05-08 Immunogens for meningitidis-A vaccines

Country Status (15)

Country Link
US (1) US8062641B2 (enExample)
EP (1) EP1885734B1 (enExample)
JP (2) JP2008540398A (enExample)
CN (1) CN101282984B (enExample)
AU (1) AU2006245440B2 (enExample)
BR (1) BRPI0611447A2 (enExample)
CA (1) CA2606890C (enExample)
ES (1) ES2533248T3 (enExample)
MX (1) MX2007013881A (enExample)
NZ (1) NZ563940A (enExample)
PL (1) PL1885734T3 (enExample)
PT (1) PT1885734E (enExample)
RU (1) RU2412944C2 (enExample)
WO (1) WO2006120576A2 (enExample)
ZA (1) ZA200710558B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2007000341A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2584927T7 (es) * 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Derivados de oligosacáridos sulfatados novedosos
SI2608805T2 (sl) 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
US9057716B2 (en) 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
CN102417521B (zh) * 2010-09-28 2014-05-07 中国医学科学院医药生物技术研究所 一种非环核苷类抗病毒药物磷酸单酯化合物的制备方法
WO2012103444A2 (en) * 2011-01-28 2012-08-02 Purdue Research Foundation Immunogenic compositions and reagents for preparing
US9616139B2 (en) 2011-07-12 2017-04-11 The General Hospital Corporation Conjugating amines
RU2476444C1 (ru) * 2011-07-15 2013-02-27 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) СПОСОБ ПОЛУЧЕНИЯ КОНЪЮГАТА НОНА-β-(1→3)-ГЛЮКОЗИДА С БЫЧЬИМ СЫВОРОТОЧНЫМ АЛЬБУМИНОМ СКВАРАТНЫМ МЕТОДОМ
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2016103771A (ru) * 2013-07-07 2017-08-11 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Синтетические вакцины против streptococcus pneumoniae 1-го типа
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
EP3110825B1 (en) * 2014-02-25 2020-12-09 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel synthetic oligomers of neisseria meningitis serogroup x and process of preparing them
CU20170046A7 (es) * 2014-10-09 2017-06-05 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd Proceso mejorado para la conjugación y conjugados sintéticos de oligosacarido-proteina novedosos obtenidos del mismo
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018173068A1 (en) * 2017-03-21 2018-09-27 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A novel synthetic neisseria meningitidis serogroup a oligomer and process for synthesizing thereof
WO2020104697A1 (en) 2018-11-22 2020-05-28 Vaxxilon Ag Stable vaccine against clostridium difficile
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN118178643B (zh) * 2024-04-28 2024-11-29 亚培烯科技(上海)有限公司 饱和α烯烃低聚物作为佐剂在动物疫苗中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US6114309A (en) * 1997-11-21 2000-09-05 Incara Research Laboratories Combinatorial library of moenomycin analogs and methods of producing same
JP4774496B2 (ja) * 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
BR0308768A (pt) * 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
PT2191844E (pt) * 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
RU2250113C2 (ru) * 2003-06-04 2005-04-20 Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова Российской академии наук Способ приготовления бивалентной вакцины для профилактики менингококковой инфекции

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Torres-Sanchez, M. I.. et al (2005) Synlett, 7:1147-1151 *

Also Published As

Publication number Publication date
EP1885734A2 (en) 2008-02-13
NZ563940A (en) 2010-11-26
JP2013136639A (ja) 2013-07-11
JP2008540398A (ja) 2008-11-20
ZA200710558B (en) 2010-04-28
ES2533248T3 (es) 2015-04-08
WO2006120576A3 (en) 2007-07-12
CN101282984B (zh) 2013-05-08
CA2606890C (en) 2014-02-04
EP1885734B1 (en) 2015-01-14
CA2606890A1 (en) 2006-11-16
US8062641B2 (en) 2011-11-22
RU2007145219A (ru) 2009-06-20
AU2006245440A1 (en) 2006-11-16
US20090304734A1 (en) 2009-12-10
MX2007013881A (es) 2008-10-22
PT1885734E (pt) 2015-03-04
JP5699174B2 (ja) 2015-04-08
PL1885734T3 (pl) 2015-08-31
WO2006120576A2 (en) 2006-11-16
BRPI0611447A2 (pt) 2010-09-08
CN101282984A (zh) 2008-10-08
RU2412944C2 (ru) 2011-02-27

Similar Documents

Publication Publication Date Title
AU2006245440B2 (en) Immunogens for meningitidis-A vaccines
EP0276516B1 (en) New oligosaccharides, immunogens and vaccines, and methods for preparing such oligosaccharides, immunogens and vaccines
US10596272B2 (en) Vaccines against Streptococcus pneumoniae serotype 5
JP2019504017A (ja) ストレプトコッカス ニューモニアエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）血清型２に対する合成ワクチン
KR100818163B1 (ko) 리보즈-리비톨-인산염의 올리고당 유도체 및 이를포함하는 백신
US20230346905A1 (en) Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME TO REMOVE CO-APPLICANT STOCKHOLM UNIVERSITY AND ADD COAPPLICANTS STEFAN OSCARSON AND PETER TEODOROVIC

FGA Letters patent sealed or granted (standard patent)